Your browser doesn't support javascript.
loading
Standardizing Health Outcomes for Lung Cancer. Adaptation of the International Consortium for Health Outcomes Measurement Set to the Spanish Setting.
Escudero-Vilaplana, Vicente; Calles, Antonio; Collado-Borrell, Roberto; Belén Marzal-Alfaro, María; Polanco, Carlos; Garrido, Carmen; Suarez, Jorge; Ortiz, Aurora; Appierto, Marilena; Comellas, Marta; Lizán, Luis.
Afiliación
  • Escudero-Vilaplana V; Hospital Pharmacy, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain.
  • Calles A; Medical Oncology, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
  • Collado-Borrell R; Hospital Pharmacy, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain.
  • Belén Marzal-Alfaro M; Hospital Pharmacy, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain.
  • Polanco C; Bristol-Myers Squibb, Madrid, Spain.
  • Garrido C; Bristol-Myers Squibb, Madrid, Spain.
  • Suarez J; Bristol-Myers Squibb, Madrid, Spain.
  • Ortiz A; Bristol-Myers Squibb, Madrid, Spain.
  • Appierto M; Outcomes'10, Castellón de la plana, Spain.
  • Comellas M; Outcomes'10, Castellón de la plana, Spain.
  • Lizán L; Outcomes'10, Castellón de la plana, Spain.
Front Oncol ; 10: 1645, 2020.
Article en En | MEDLINE | ID: mdl-32984036
ABSTRACT

Purpose:

Lung cancer (LC) and its treatment impose a significant burden on patients' life. However, patient-centered outcomes are rarely collected during patient follow-up. Filling this gap, the International Consortium for Health Outcomes Measurement (ICHOM) developed a standard set of variables for newly diagnosed LC patients. In order to facilitate the use of this standard set, the project aims to adapt it to the Spanish setting.

Methods:

The variables (instrument and periodicity) to be included in Spanish standard set were selected through consensus during 4 nominal groups (13 oncologists, 14 hospital pharmacists, 4 hospital managers and 3 LC patients), under the supervision of a Scientific Committee (1 oncologist, 3 hospital pharmacists, 2 LC patients advocates).

Results:

The variables agreed upon included (1) case-mix demographic [age, sex, education and social-family support], clinical [weight loss, smoking status, comorbidities (Charlson index), pulmonary function (FEV-1)], tumor [histology, clinical, and pathological stage (TNM), EGFR, ALK, ROS-1, PD-L1] and treatment factors [intent and completion] and (2)

outcomes:

degree of health [performance status (ECOG) and quality-of-life (EQ-5D, LCSS)], survival [overall survival and cause of death], quality of death [place of death, end-of-life care and palliative care, death aligned with living will], treatment complications, and others [date of diagnosis and treatment initiation, productivity loss (sick leave)].

Conclusion:

The adaptation of ICHOM standard set to the Spanish setting pave the way to standardize the collection of variables in LC.
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Front Oncol Año: 2020 Tipo del documento: Article País de afiliación: España

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Front Oncol Año: 2020 Tipo del documento: Article País de afiliación: España